---
title: "Key facts: 22nd Century Group Q4 2025 revenues at $3.6M; operating loss at $2.8M"
description: "22nd Century Group reported Q4 2025 net revenues of about $3.6 million, down from $4.0 million in Q3. Total revenues for 2025 are expected to be $17.6 million.122nd Century Group reported an operating"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276519541.md"
published_at: "2026-02-21T20:03:02.000Z"
---

# Key facts: 22nd Century Group Q4 2025 revenues at $3.6M; operating loss at $2.8M

> 22nd Century Group reported Q4 2025 net revenues of about $3.6 million, down from $4.0 million in Q3. Total revenues for 2025 are expected to be $17.6 million.122nd Century Group reported an operating income of USD -2.8 million for the fourth quarter.2

-   22nd Century Group reported Q4 2025 net revenues of about $3.6 million, down from $4.0 million in Q3. Total revenues for 2025 are expected to be $17.6 million.1
-   22nd Century Group reported an operating income of USD -2.8 million for the fourth quarter.2

### Related Stocks

- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [XXII.US - 22nd Century](https://longbridge.com/en/quote/XXII.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 22nd Century Group Announces 1-for-15 Reverse Stock Split | 22nd Century Group Inc. has announced a 1-for-15 reverse stock split of its common shares, effective January 26, 2026. T | [Link](https://longbridge.com/en/news/273375994.md) |
| Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora | Needham analyst Ami Fadia has maintained a Buy rating on Neumora Therapeutics, Inc. with a price target of $8.00, citing | [Link](https://longbridge.com/en/news/275644413.md) |
| Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update | Beyond Air, Inc. reported a 105% year-over-year revenue increase to $2.2 million for fiscal Q3 2026, maintaining its rev | [Link](https://longbridge.com/en/news/275902609.md) |
| IQVIA Q4 revenue rises 10.3%, beats analyst estimates | IQVIA reported a 10.3% increase in Q4 revenue, surpassing analyst expectations. The adjusted EPS also exceeded forecasts | [Link](https://longbridge.com/en/news/274969609.md) |
| BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference \| BYSI Stock News | BeyondSpring Inc. (NASDAQ: BYSI) will participate in the Immuno-Oncology 360° Conference from February 10-12, 2026, in B | [Link](https://longbridge.com/en/news/275315920.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.